Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice

Yutaka Ogasawara, Hiroyoshi Doihara, Kouji Shiroma, Yoshiaki Kanaya, Nobuyoshi Shimizu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The antitumor effects of an experimental chemoendocrine therapy combining a new pure antiestrogen ICI 182780 and 5-fluorouracil (5-FU) were studied on MCF-7 human breast cancer cells implanted in nude mice. ICI 182780 had a dose-dependent antitumor activity, which was potentiated by the concomitant use of 5-FU. When compared with the control group, the estrogen receptor (ER) level in the ICI 182780 group was lower and that in the combination group was markedly lower. Cell cycle analysis by flow cytometry (FCM) resulted in a lower percentage of S-phase cells (%S) in the treated mice. No significant difference was observed in the 5-FU concentrations in tumor cells, while the 5-FU content in RNA was significantly higher in the combination group. The changes in free thymidylate synthetase (TS) concentration indicated TS synthesis after the administration of 5-FU to be more greatly suppressed in the combination group than in the 5-FU group. These results suggest that ICI 182780 and 5-FU exert their combination effect mainly on ER-positive cells, and that the suppression of TS synthesis in tumor cells and the potentiation of the 5-FU-induced metabolic dysfunction of RNA are thus involved in the mode of action of this combination therapy.

Original languageEnglish
Pages (from-to)149-156
Number of pages8
JournalSurgery Today
Volume29
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Investigational Therapies
Estrogen Receptor Modulators
Nude Mice
Fluorouracil
Breast Neoplasms
Thymidylate Synthase
Estrogen Receptors
RNA
S Phase
Neoplasms
Cell Cycle
Flow Cytometry
Control Groups
fulvestrant

Keywords

  • 5-fluorouracil
  • Breast cancer
  • Chemoendocrine therapy
  • Nude mouse
  • Pure antiestrogen

ASJC Scopus subject areas

  • Surgery

Cite this

Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice. / Ogasawara, Yutaka; Doihara, Hiroyoshi; Shiroma, Kouji; Kanaya, Yoshiaki; Shimizu, Nobuyoshi.

In: Surgery Today, Vol. 29, No. 2, 1999, p. 149-156.

Research output: Contribution to journalArticle

@article{283369940bc34932b7fa335b278490ee,
title = "Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice",
abstract = "The antitumor effects of an experimental chemoendocrine therapy combining a new pure antiestrogen ICI 182780 and 5-fluorouracil (5-FU) were studied on MCF-7 human breast cancer cells implanted in nude mice. ICI 182780 had a dose-dependent antitumor activity, which was potentiated by the concomitant use of 5-FU. When compared with the control group, the estrogen receptor (ER) level in the ICI 182780 group was lower and that in the combination group was markedly lower. Cell cycle analysis by flow cytometry (FCM) resulted in a lower percentage of S-phase cells ({\%}S) in the treated mice. No significant difference was observed in the 5-FU concentrations in tumor cells, while the 5-FU content in RNA was significantly higher in the combination group. The changes in free thymidylate synthetase (TS) concentration indicated TS synthesis after the administration of 5-FU to be more greatly suppressed in the combination group than in the 5-FU group. These results suggest that ICI 182780 and 5-FU exert their combination effect mainly on ER-positive cells, and that the suppression of TS synthesis in tumor cells and the potentiation of the 5-FU-induced metabolic dysfunction of RNA are thus involved in the mode of action of this combination therapy.",
keywords = "5-fluorouracil, Breast cancer, Chemoendocrine therapy, Nude mouse, Pure antiestrogen",
author = "Yutaka Ogasawara and Hiroyoshi Doihara and Kouji Shiroma and Yoshiaki Kanaya and Nobuyoshi Shimizu",
year = "1999",
doi = "10.1007/s005950050376",
language = "English",
volume = "29",
pages = "149--156",
journal = "Japanese Journal of Surgery",
issn = "0941-1291",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice

AU - Ogasawara, Yutaka

AU - Doihara, Hiroyoshi

AU - Shiroma, Kouji

AU - Kanaya, Yoshiaki

AU - Shimizu, Nobuyoshi

PY - 1999

Y1 - 1999

N2 - The antitumor effects of an experimental chemoendocrine therapy combining a new pure antiestrogen ICI 182780 and 5-fluorouracil (5-FU) were studied on MCF-7 human breast cancer cells implanted in nude mice. ICI 182780 had a dose-dependent antitumor activity, which was potentiated by the concomitant use of 5-FU. When compared with the control group, the estrogen receptor (ER) level in the ICI 182780 group was lower and that in the combination group was markedly lower. Cell cycle analysis by flow cytometry (FCM) resulted in a lower percentage of S-phase cells (%S) in the treated mice. No significant difference was observed in the 5-FU concentrations in tumor cells, while the 5-FU content in RNA was significantly higher in the combination group. The changes in free thymidylate synthetase (TS) concentration indicated TS synthesis after the administration of 5-FU to be more greatly suppressed in the combination group than in the 5-FU group. These results suggest that ICI 182780 and 5-FU exert their combination effect mainly on ER-positive cells, and that the suppression of TS synthesis in tumor cells and the potentiation of the 5-FU-induced metabolic dysfunction of RNA are thus involved in the mode of action of this combination therapy.

AB - The antitumor effects of an experimental chemoendocrine therapy combining a new pure antiestrogen ICI 182780 and 5-fluorouracil (5-FU) were studied on MCF-7 human breast cancer cells implanted in nude mice. ICI 182780 had a dose-dependent antitumor activity, which was potentiated by the concomitant use of 5-FU. When compared with the control group, the estrogen receptor (ER) level in the ICI 182780 group was lower and that in the combination group was markedly lower. Cell cycle analysis by flow cytometry (FCM) resulted in a lower percentage of S-phase cells (%S) in the treated mice. No significant difference was observed in the 5-FU concentrations in tumor cells, while the 5-FU content in RNA was significantly higher in the combination group. The changes in free thymidylate synthetase (TS) concentration indicated TS synthesis after the administration of 5-FU to be more greatly suppressed in the combination group than in the 5-FU group. These results suggest that ICI 182780 and 5-FU exert their combination effect mainly on ER-positive cells, and that the suppression of TS synthesis in tumor cells and the potentiation of the 5-FU-induced metabolic dysfunction of RNA are thus involved in the mode of action of this combination therapy.

KW - 5-fluorouracil

KW - Breast cancer

KW - Chemoendocrine therapy

KW - Nude mouse

KW - Pure antiestrogen

UR - http://www.scopus.com/inward/record.url?scp=0032988415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032988415&partnerID=8YFLogxK

U2 - 10.1007/s005950050376

DO - 10.1007/s005950050376

M3 - Article

C2 - 10030740

AN - SCOPUS:0032988415

VL - 29

SP - 149

EP - 156

JO - Japanese Journal of Surgery

JF - Japanese Journal of Surgery

SN - 0941-1291

IS - 2

ER -